Maravai LifeSciences (MRVI) Misses Q2 EPS by 6c

Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.05), $0.06 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $68.91 million versus the consensus estimate of $71.13 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• Lucid Capital Markets Starts Bain Capital Specialty Finance (BCSF) at Neutral